Back
Lucid Diagnostics
IPOLUCD.NASDAQPast

Lucid Diagnostics

Services-Commercial Physical & Biological Research

Company website ↗
Foundation year: 2018
IPO date
13/10/2021

About

Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company. Lucid is focused on the millions of patients with gastroesophageal disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid’s EsoGuard® Esophageal DNA Test, performed on samples collected in a brief noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, is the first and only commercially available diagnostic test capable of serving as a widespread screening tool to prevent cancer and cancer deaths through early detection of esophageal precancer in at-risk GERD patients.


Number of employees

1 - 10


Headquarters

New York, New York, US

Underwriters

PAVmed